5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for fat loss and metabolic effects. NNMT is overexpressed in adipose (fat) tissue in obese individuals and is sometimes called the 'obesity enzyme.' By inhibiting NNMT, 5-Amino-1MQ theoretically raises cellular NAD+ and SAM levels, boosting metabolism in fat cells.

How does 5-Amino-1MQ cause fat loss?

NNMT consumes SAM (S-adenosylmethionine) and produces 1-methylnicotinamide. In fat tissue, high NNMT activity depletes SAM and NAD+ precursors, reducing metabolic rate. 5-Amino-1MQ inhibits NNMT, which: raises SAM levels (needed for epigenetic methylation), restores NAD+ pathway flux, and increases energy expenditure in adipocytes. In mouse models, NNMT-inhibited mice ate the same but gained significantly less fat.

What does the research show for 5-Amino-1MQ?

Published research (Neelakantan et al., 2018, PMID: 29155147) showed a potent small-molecule NNMT inhibitor reduced body weight and white adipose mass in high-fat diet mouse models without changes in food intake. A later study (Babula et al., 2024, PMID: 39161060) tested 5-Amino-1MQ (5A1MQ) directly in diet-induced obese mice and found it limited fat mass gains and improved glucose tolerance. These are preclinical studies — no human trials have been published.

What is the typical 5-Amino-1MQ dose?

Research compound dosing is extrapolated from animal studies. Community protocols typically use 50-150mg per day, orally. Some protocols use 50mg twice daily. 5-Amino-1MQ is orally bioavailable. There are no established human clinical doses — all human use is off-label extrapolation from mouse study doses scaled by body weight.

Safety data is very limited. Preclinical mouse studies showed no obvious toxicity. No human safety trials have been published. The mechanism (NNMT inhibition affecting NAD+ and SAM metabolism) could potentially affect epigenetic processes throughout the body. Long-term effects are unknown. Use with caution — this is an early-stage research compound with minimal human safety data.

Fat Loss Research · NNMT Inhibitor · Metabolic Compound

5-Amino-1MQ: Targeting the "Obesity Enzyme" for Fat Loss

📄 2 PubMed citations

By Steve B, HighPeptides Editor

Last updated: April 2026

5-Amino-1MQ is one of the most mechanistically interesting fat loss compounds in the research space. It inhibits NNMT — an enzyme overexpressed in obese adipose tissue that acts as a metabolic brake. In mouse models, NNMT inhibition produced significant fat loss without reduced food intake. No human trials yet, but the mechanism is compelling.

🧪 Buy 5-Amino-1MQ at Swiss Chems →

NNMT

Target Enzyme
Nicotinamide N-methyltransferase — the "obesity enzyme"

Oral

Bioavailability
Unlike most fat loss peptides — orally active

NAD+

Downstream Effect
Raises NAD+ and SAM in adipose tissue

📋 On this page

How NNMT Inhibition Drives Fat Loss
What the Research Shows
Side Effects & Safety Concerns
Key Takeaways
Related Fat Loss Compounds
🔬 Research-Grade Peptides
Evidence-Based Metabolic Supplements

Mechanism of Action

How NNMT Inhibition Drives Fat Loss

The mechanism is elegant: block an enzyme that fat cells use to suppress their own metabolism. Remove the brake — the cells burn more energy.

🔴

What NNMT Does (The Problem)

NNMT (nicotinamide N-methyltransferase) consumes SAM (S-adenosylmethionine) to methylate nicotinamide, producing 1-methylnicotinamide. This depletes SAM and drains NAD+ precursors. In obese adipose tissue, NNMT is upregulated 3-5x vs. lean tissue. The result: metabolically suppressed fat cells that resist energy expenditure. NNMT becomes a metabolic governor locking in obesity.

✅

What NNMT Inhibition Does (The Solution)

5-Amino-1MQ inhibits NNMT, stopping SAM depletion. Restored SAM supports epigenetic methylation processes, and restored NAD+ precursor flux supports sirtuin activity and mitochondrial biogenesis in fat cells. The net effect: adipocytes resume normal energy expenditure. In Neelakantan et al. (2018, PMID: 29155147), treated mice showed reduced body weight and white adipose mass with no change in food intake.

⚡

NAD+ and Sirtuin Activation

NAD+ is required for SIRT1, SIRT3, and other sirtuins — metabolic enzymes that regulate energy expenditure, fatty acid oxidation, and mitochondrial function. By restoring NAD+ precursor availability, NNMT inhibition indirectly boosts sirtuin activity. This overlaps mechanistically with NMN/NAD+ supplementation but acts specifically in adipose tissue rather than systemically.

📉

Lipid Profile Effects

Alongside fat loss, NNMT inhibition has shown an effect on circulating lipids in animal models. Neelakantan et al. (2018, PMID: 29155147) reported that diet-induced obese mice treated with a potent NNMT inhibitor had significantly lowered plasma total cholesterol in addition to reduced body weight and adipose mass. Note: this is a preclinical total-cholesterol finding — specific LDL-C effects and any PCSK9-related mechanism have not been established for this compound.

Evidence Review

What the Research Shows

Preclinical evidence is compelling. Human evidence is absent. The gap between mouse studies and human outcomes is a critical caveat.

NNMT Inhibition (in vitro)

Confirmed potent NNMT inhibitor — IC50 well-characterized

Very Strong

Fat Mass Reduction (Mouse HFD Models)

Neelakantan et al. 2018 (PMID: 29155147) — significant body weight and adipose mass reduction

Strong

Plasma Cholesterol Reduction (Mice)

Lowered plasma total cholesterol in treated DIO mice (PMID: 29155147) — LDL-specific / PCSK9 effects not established

Moderate (preclinical)

Human Clinical Evidence

No published human trials — community reports only

—

Safety

Side Effects & Safety Concerns

Very limited human safety data. Mouse study safety appeared favorable, but SAM/NAD+ pathway effects systemically have unknown long-term implications.

GI Discomfort (community reports)

Nausea, loose stools — common at start of protocol

~20%

Headache (initial)

First 1-2 weeks — may relate to SAM/methylation changes

~12%

Increased Energy / Warmth

Reported by community as positive effect — thermogenic signal

~30%

Serious / Systemic Adverse Events

None confirmed in mice or community reports — unknown in humans long-term

Unknown

Summary

Key Takeaways

✅ What We Know

Potent, well-characterized NNMT inhibitor in vitro
Mouse HFD studies show significant body weight and fat mass reduction (PMID: 29155147)
Lowered plasma total cholesterol in treated mice is an interesting secondary effect (PMID: 29155147)
Orally bioavailable — unlike most fat loss peptides (no injection required)
SAM/NAD+ restoration mechanism is mechanistically sound and published

⚠️ What We Don't Know

No human clinical trials published — all efficacy data is preclinical
Mouse-to-human translation for NNMT inhibition is unproven
Long-term systemic SAM/NAD+ pathway effects are unknown
NNMT inhibition in non-adipose tissues may have unintended effects
Optimal human dose is extrapolated — not established by human pharmacokinetics

Related Research

💉

AOD-9604 Guide

HGH fragment peptide studied for fat loss

→ ⚖️

Best Peptide for Weight Loss

Complete comparison of fat loss compounds

→ ⚡

NAD+ Guide

The downstream pathway 5-Amino-1MQ activates

→ 🔬

Peptide Quality Testing

Verify your compound before use

→

🔬 Research-Grade Peptides

Swiss Chems

Third-party HPLC tested with published COAs. One of the most established research peptide vendors.

Browse Swiss Chems →

Affiliate link — supports HighPeptides at no extra cost

Metabolic Support Stack

Evidence-Based Metabolic Supplements

Evidence-backed metabolic support compounds with better human safety profiles — useful alongside or as alternatives to research compounds.

NMN 500mgNAD+ precursor — shares downstream pathway with 5-Amino-1MQ. Human trials exist. Berberine 500mgMultiple human trials for metabolic health — AMPK activator Resveratrol 500mgSirtuin activator — overlapping NAD+/SIRT1 pathway activation Ubiquinol CoQ10 200mgMitochondrial energy support — complements metabolic activation Alpha Lipoic Acid 600mgInsulin sensitizer + mitochondrial antioxidant with human evidence

⚠️ Research Purposes Only

5-Amino-1MQ is not approved by the FDA for any use. This content is educational only. No human clinical trials for safety or efficacy have been published. Use of this compound involves unknown risks. Consult a physician before use. HighPeptides does not recommend self-administration of unapproved research compounds.